Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin Delayed Release for Post-operative Crohn's Disease Recurrence
NCT03537157Phase 2Terminated
- Sponsor
- Alfasigma
- Start
- Nov 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rifaximin in Crohn's disease, sponsored by Alfasigma. Started Nov 2017; status: terminated.
02
Drugs
rifaximin
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03537157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03537157.